Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Coated Cesol vs Biltricide
NCT04314037Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of praziquantel in schistosomiasis, clonorchiasis and opisthorchiasis (2 arms), sponsored by Merck KGaA. Primary endpoints: Maximum Observed Plasma Concentration of Racemic-Praziquantel and Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration of Racemic-Praziquantel. Started Jun 2020; status: completed.
02
Drugs
praziquantel
03
Conditions
schistosomiasisclonorchiasisopisthorchiasis
Beyond the preview
Go deeper on NCT04314037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314037.